David C. Binder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
David C. Binder has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Hans Schreiber
Committee on Cancer Biology, University of Chicago, Chicago, IL, USA; Department of Pathology, University of Chicago, Chicago, IL, USA; Committee on Immunology, The University of Chicago, Chicago, IL, USA
4 shared publicationsAinhoa Arina
Department of Pathology, University of Chicago, Chicago, IL, USA; Committee on Immunology, The University of Chicago, Chicago, IL, USA
2 shared publications- Derek A. Wainwright
Department of Cancer Biology, Stritch School of Medicine, Loyola University, Maywood, IL 60153, USA
2 shared publications Ming Zhao
AntiCancer Inc. , San Diego, CA, USA
2 shared publicationsRobert M. Hoffman
AntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA
2 shared publicationsAndrew A. Davis
Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Il, USA
1 shared publication
Latest Publications
- Open Access
- 18 February 2016
- Published by Taylor & Francis in OncoImmunology
- Vol. 5 (6) , e1130207
Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium
We recently reported that therapeutic vaccination with live tumor antigen-producing Salmonella typhimurium rescues dysfunctional endogenous T cell responses and eradicates long-established tumors refractory to αCTLA-4 and αPD-L1 checkpoint inhibitor blockade. Here, we show that live intravenously injected or heat-killed (HK) intratumorally injected Salmonella typhimurium, even when not producing tumor antigen, synergize with adoptive T cell therapy to eradicate tumors. These data demonstrate that the combination of adoptive T cell transfer with the injection of live or dead Salmonella typhimurium is a promising approach for cancer treatment.
- 18 February 2016
- Published by Taylor & Francis in OncoImmunology
- Vol. 5 (6) , e1130207
Open AccessTumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium
We recently reported that therapeutic vaccination with live tumor antigen-producing Salmonella typhimurium rescues dysfunctional endogenous T cell responses and eradicates long-established tumors refractory to αCTLA-4 and αPD-L1 checkpoint inhibitor blockade. Here, we show that live intravenously injected or heat-killed (HK) intratumorally injected Salmonella typhimurium, even when not producing tumor antigen, synergize with adoptive T cell therapy to eradicate tumors. These data demonstrate that the combination of adoptive T cell transfer with the injection of live or dead Salmonella typhimurium is a promising approach for cancer treatment.
- 1 August 2015
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 21 (8) , 463-465
Radiotherapy and immune checkpoint blockade: potential interactions and future directions
- 1 August 2015
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 21 (8) , 463-465
Radiotherapy and immune checkpoint blockade: potential interactions and future directions
- Open Access
- 5 June 2015
- Published by Taylor & Francis in OncoImmunology
- Vol. 5 (2) , e1082027
Immunotherapy for cancer in the central nervous system: Current and future directions
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and still remains incurable. Although immunotherapeutic vaccination against GBM has demonstrated immune-stimulating activity with some promising survival benefits, tumor relapse is common, highlighting the need for additional and/or combinatorial approaches. Recently, antibodies targeting immune checkpoints were demonstrated to generate impressive clinical responses against advanced melanoma and other malignancies, in addition to showing potential for enhancing vaccination and radiotherapy (RT). Here, we summarize the current knowledge of central nervous system (CNS) immunosuppression, evaluate past and current immunotherapeutic trials and discuss promising future immunotherapeutic directions to treat CNS-localized malignancies.
- 5 June 2015
- Published by Taylor & Francis in OncoImmunology
- Vol. 5 (2) , e1082027
Open AccessImmunotherapy for cancer in the central nervous system: Current and future directions
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and still remains incurable. Although immunotherapeutic vaccination against GBM has demonstrated immune-stimulating activity with some promising survival benefits, tumor relapse is common, highlighting the need for additional and/or combinatorial approaches. Recently, antibodies targeting immune checkpoints were demonstrated to generate impressive clinical responses against advanced melanoma and other malignancies, in addition to showing potential for enhancing vaccination and radiotherapy (RT). Here, we summarize the current knowledge of central nervous system (CNS) immunosuppression, evaluate past and current immunotherapeutic trials and discuss promising future immunotherapeutic directions to treat CNS-localized malignancies.
- 15 January 2014
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 74 (2) , 632
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors—Letter
The study by Duraiswamy and colleagues has much translational relevance (1) as new clinical data demonstrate that antagonistic antibodies blocking PD-1 and/or CTLA-4 provide strong responses to some but not all patients (2–4). Interestingly, the limited objective response rate seems to also apply to patients with a presumed preexisting tumor-reactive T-cell response (3, 5). Therefore, the importance of the Duraiswamy study is that it identified an approach that may extend objective response rates to a greater percentage of patients.
- 15 January 2014
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 74 (2) , 632
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors—Letter
The study by Duraiswamy and colleagues has much translational relevance (1) as new clinical data demonstrate that antagonistic antibodies blocking PD-1 and/or CTLA-4 provide strong responses to some but not all patients (2–4). Interestingly, the limited objective response rate seems to also apply to patients with a presumed preexisting tumor-reactive T-cell response (3, 5). Therefore, the importance of the Duraiswamy study is that it identified an approach that may extend objective response rates to a greater percentage of patients.
- Open Access
- 1 December 2013
- Published by Taylor & Francis in OncoImmunology
- Vol. 2 (12) , e26704
High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies
We tested how to eradicate long-established immunogenic tumors that were resistant to the monoclonal antibody-mediated blockade of PD-L1 (PD-1 ligand 1) and cytotoxic T lymphocyte-associated protein 4 (CTLA4). Bacterial vaccination with a tumor-specific peptide exhibiting a high affinity for its respective MHC molecule consistently eradicated tumors when combined with a PD-L1 blocking antibody. This approach can be translated to the clinic by combining cancer cell whole-exome sequencing with algorithms to identify mutant peptides with high peptide-MHC binding affinity.
- 1 December 2013
- Published by Taylor & Francis in OncoImmunology
- Vol. 2 (12) , e26704
Open AccessHigh-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies
We tested how to eradicate long-established immunogenic tumors that were resistant to the monoclonal antibody-mediated blockade of PD-L1 (PD-1 ligand 1) and cytotoxic T lymphocyte-associated protein 4 (CTLA4). Bacterial vaccination with a tumor-specific peptide exhibiting a high affinity for its respective MHC molecule consistently eradicated tumors when combined with a PD-L1 blocking antibody. This approach can be translated to the clinic by combining cancer cell whole-exome sequencing with algorithms to identify mutant peptides with high peptide-MHC binding affinity.
- 1 August 2013
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 1 (2) , 123-133
Antigen-Specific Bacterial Vaccine Combined with Anti-PD-L1 Rescues Dysfunctional Endogenous T Cells to Reject Long-Established Cancer
Immunogenic tumors grow progressively even when heavily infiltrated by CD8+ T cells. We investigated how to rescue CD8+ T-cell function in long-established immunogenic melanomas that contained a high percentage of endogenous PD-1+ tumor-specific CD8+ T cells that were dysfunctional. Treatment with αPD-L1– and αCTLA-4–blocking antibodies did not prevent tumors from progressing rapidly. We then tested exogenous tumor-specific antigen delivery into tumors using Salmonella Typhimurium A1-R (A1-R) to increase antigen levels and generate a proinflammatory tumor microenvironment. Antigen-producing A1-R rescued the endogenous tumor-specific CD8+ T-cell response: Proliferation was induced in the lymphoid organs and effector function was recovered in the tumor. Treatment with antigen-producing A1-R led to improved mouse survival and resulted in 32% rejection of long-established immunogenic melanomas. Following treatment with antigen-producing A1-R, the majority of tumor-specific CD8+ T cells still expressed a high level of PD-1 in the tumor. Combining antigen-producing A1-R with αPD-L1-blocking antibody enhanced the expansion of tumor-specific CD8+ T cells and resulted in 80% tumor rejection. Collectively, these data show a powerful new therapeutic approach to rescue dysfunctional endogenous tumor-specific CD8+ T cells and eradicate advanced immunogenic tumors. Cancer Immunol Res; 1(2); 123–33. ©2013 AACR.
- 1 August 2013
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 1 (2) , 123-133
Antigen-Specific Bacterial Vaccine Combined with Anti-PD-L1 Rescues Dysfunctional Endogenous T Cells to Reject Long-Established Cancer
Immunogenic tumors grow progressively even when heavily infiltrated by CD8+ T cells. We investigated how to rescue CD8+ T-cell function in long-established immunogenic melanomas that contained a high percentage of endogenous PD-1+ tumor-specific CD8+ T cells that were dysfunctional. Treatment with αPD-L1– and αCTLA-4–blocking antibodies did not prevent tumors from progressing rapidly. We then tested exogenous tumor-specific antigen delivery into tumors using Salmonella Typhimurium A1-R (A1-R) to increase antigen levels and generate a proinflammatory tumor microenvironment. Antigen-producing A1-R rescued the endogenous tumor-specific CD8+ T-cell response: Proliferation was induced in the lymphoid organs and effector function was recovered in the tumor. Treatment with antigen-producing A1-R led to improved mouse survival and resulted in 32% rejection of long-established immunogenic melanomas. Following treatment with antigen-producing A1-R, the majority of tumor-specific CD8+ T cells still expressed a high level of PD-1 in the tumor. Combining antigen-producing A1-R with αPD-L1-blocking antibody enhanced the expansion of tumor-specific CD8+ T cells and resulted in 80% tumor rejection. Collectively, these data show a powerful new therapeutic approach to rescue dysfunctional endogenous tumor-specific CD8+ T cells and eradicate advanced immunogenic tumors. Cancer Immunol Res; 1(2); 123–33. ©2013 AACR.